In particular, approximately 80%–90% of all BRAF mutations observed in colon cancer patients are represented by the missense mutation 1799T>A within the kinase domain of BRAF (BRAF c.1799T>A), which leads to the substitution of a valine to a glutamic acid at the position 600 (BRAFV600E). Here, BRAF is linked to malignant colon neoplasm.